MYG1 exonuclease (MYG1)

MYG1 exonuclease is a conserved, dually localized 3'-5' RNA exonuclease found in both the nucleus (nucleolus) and mitochondria of eukaryotic cells[1][2][3][4][10]. It processes specific RNA substrates, including pre-ribosomal RNA in the nucleolus—contributing to ribosome assembly and cytoplasmic translation—and mitochondrial RNAs, influencing mitochondrial protein translation and overall mitochondrial function. MYG1 contains a metal-dependent hydrolase domain (UPF0160) and is ubiquitously expressed in human tissues, with the highest levels in the testis and during specific stages of development[2][8]. Loss of MYG1 affects factors involved in tissue patterning and immune processes. It has been linked in some studies to a possible role in vitiligo (a depigmenting disorder), as well as being mentioned in genetic contexts for cone-rod dystrophy and congenital myopathy[1][2][3]. No drugs, mechanisms of action for therapeutic targeting, biomarkers, or safety concerns are reported for MYG1. The current evidence classifies MYG1 as a fundamental enzyme involved in the cross-regulation of nuclear and mitochondrial gene expression rather than as a therapeutic target.

Other names

MYG1C12orf10MYGGamm1melanocyte related genemelanocyte proliferating gene 1MST024MSTP024UPF0160 protein MYG1, mitochondrialmelanocyte proliferating gene 1, melanocyte related